BNET Industries
- Private
- CA
Dow Jones Description
Only 30 minutes from the heart of downtown Vancouver, the University of British Columbia holds an international reputation for excellence in advanced research and learning. The spectacular UBC campus is a 'must-see' for any visitor to the city -- where snow-capped mountains meet ocean, and breathtaking vistas greet you around every corner. The university boasts some of the city's best attractions & recreation facilities, including the Museum of Anthropology, the Chan Centre for the Performing Arts, the UBC Botanical Garden and Centre for Plant Research, and endless opportunities to explore forested trails in the adjoining 763-hectare Pacific Spirit Regional Park.
Contact Information
2329 West Mall
Vancouver, British Columbia V6T 1Z4
604.822.2211
NAICS Code Colleges, Universities, and Professional Schools: 611310
News & Analysis
Filter by
dr. and healthcare and university of british columbia - All News and Analysis
EnWave Files bioREV Equipment and Methodology Patent for Vaccine Dehydration.
VANCOUVER, BRITISH COLUMBIA, Sep 14, 2007 CCNMatthews via COMTEX -- EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") wishes to report that Dr. Tim Durance and EnWave Senior Engineer Leon Fu have filed a US patent application on behalf of EnWave to protect the Company's ...
EnWave Corporation: Vaccine, Drug Process Patents Filed.
VANCOUVER, BRITISH COLUMBIA, Feb 22, 2007 CCNMatthews via COMTEX -- EnWave Corporation (TSX VENTURE:ENW) (the "Company") wishes to report that Dr. Tim Durance, in conjunction with other researchers at the University of British Columbia UBC, has filed US CIP and international PCT patent applications to protect...
MIV Therapeutics Highlights 2005 Scientific and Strategic Milestones in Development of New Generation Biomedical Technologies; Year-End Report Cites Achievements in Breakthrough Drug Delivery and Other Solutions for Multi-Billion-Dollar Markets
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, has reported significant progress in a report outlining the achievement of numerous key strategic, corporate and technological objectives for 2005. "The past year has been a time of...
Meridian Receives Endorsement from Recognised Cardiologist for Digital Pulse Analyzer
SEOUL, Korea -- Meridian Co., Ltd. ("Meridian") (OTCBB:MRDAF) announced today that it has received a positive endorsement of its Digital Pulse Analyzer product from Dr. Saul Isserow. The study performed by Dr. Isserow was undertaken completely independently without any input or influence by any Meridian Co., Ltd....
Meridian Receives Endorsement from Recognised Cardiologist for Digital Pulse Analyzer.
SEOUL, KOREA, Dec 1, 2005 CCNMatthews via COMTEX -- Meridian Co., Ltd. ("Meridian") (OTCBB:MRDAF) announced today that it has received a positive endorsement of its Digital Pulse Analyzer product from Dr. Saul Isserow. The study performed by Dr. Isserow was undertaken completely independently without any input...
MIV Therapeutics' Passive Stent Coatings Accepted for Presentation at Prestigious World Conference on Cardiovascular Therapy; Interim Results of Animal Trials of Proprietary HAp Coating to be Detailed at TCT 2005 Conference
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies for the treatment of cardiovascular disease, announced that interim results of a long-term animal study of its proprietary ultra-thin Hydroxyapatite coating will be featured at this year's 17th annual Transcatheter Cardiovascular...
MIV Therapeutics Builds Strength of Drug-Delivery Technologies Program with Appointment Of Dr. Dean-Mo Lui as Chief Scientist
VANCOUVER, British Columbia -- Industry-Renowned Scientist Brings Extensive Leadership in Development of Advanced Bioceramics and Biomedical Industry MIV Therapeutics, Inc. (OTCBB: MIVT) a developer of next-generation biocompatible stent coatings and drug delivery technologies, today announced the addition of Dr. Dean-Mo Liu, Ph.D., to the post of Chief Scientist, Drug...
MIV Therapeutics Announces 2004 Year-End Review: Milestones Achieved in Development of Revolutionary Coatings for Medical Devices; Technology Increases Body's Acceptance of Implanted Devices, Provides Advanced Therapeutic Functionality
VANCOUVER, British Columbia -- MIV Therapeutics Inc. (OTCBB:MIVT), a developer of next-generation drug-eluting coatings that inhibit the rejection of implanted medical devices, has announced the Company's successful achievement of all key milestones planned in its 2004 research and development program. The Company is progressing toward commercialization of a revolutionary new...
CIHR, Media Advisory: Minister Owen Announces Health Research Projects for British Columbia.
OTTAWA, ONTARIO, Apr 8, 2004 CCNMatthews via COMTEX WHEN Thursday, April 8, 2004 9:50 a.m. - 10:45 a.m. local time ...
CIHR, Media Advisory: Minister Owen Announces Health Research Projects for British Columbia.
OTTAWA, ONTARIO, Apr 7, 2004 CCNMatthews via COMTEX WHEN Thursday, April 8, 2004 9:50 a.m. - 10:45 a.m. local time ...
- 1
- 2



